A Phase 2 Trial in Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
Latest Information Update: 08 Mar 2025
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms TURANDORELA
Most Recent Events
- 27 Feb 2024 Status changed from not yet recruiting to recruiting.
- 06 Feb 2024 New trial record